Modulation of MicroRNAs by Phytochemicals in Cancer: Underlying Mechanisms and Translational Significance

Srivastava, Sanjeev K.; Arora, Sumit; Averett, Courey; Singh, Seema; Singh, Ajay P.

doi:10.1155/2015/848710

Cited by 60 publications

(48 citation statements)

References 109 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…future science group www.futuremedicine.com Natural products are important and valuable resources for drug development, with a long history of use in treating human ailments, particularly for almost all kinds of cancer [21]. Early drug discovery was based on screening of a large number of natural and synthetic compounds.…”

Section: Discussionmentioning

confidence: 99%

The Mechanistic Antitumor Study of Myricanol 5-Fluorobenzyloxy Ether in Human Leukemic Cell Hl-60

Dai

Fan

Ren³

et al. 2017

Future Med. Chem.

View full text Add to dashboard Cite

Aim:The aim of the study was to explore the growth inhibitory effect of myricanol 5-fluorobenzyloxy ether (5FEM) and the underlying mechanism in human leukemic cells HL-60. Materials & methods: 5FEM was obtained by chemical modification of myricanol with fluorobenzyloxy ether at the OH(5) position. The cytotoxicity, cell apoptosis, cell cycle and the expression of key apoptosis-related genes in HL-60 were evaluated. Results & conclusion: 5FEM can significantly inhibited growth of HL-60 cells, increased the G2/M population and upregulated the expression of Bax, Fas, FasL, caspase-9 and p21 and downregulated that of Bcl-2 and survivin. The results enhance our understanding of 5FEM and aid the discovery of novel myricanol derivatives as potential antitumor agents. The incidence and mortality of cancer have been increasing in China [1]. About 4,292,000 new cases of cancer and 2,814,000 cancer-related deaths were estimated in China in 2015 [2]. It was reported that leukemia is the sixth leading cause of cancer death [3].Both genetic and environmental factors have been reported to cause of leukemia [4,5]. Combination of chemotherapy, radiation therapy and bone marrow transplant are involved in treatment of leukemia [6]. But these treatments have limitations because of a high probability of relapse and toxicity. Traditional Chinese medicine and natural plants have been used in the treatment of cancer for thousands of years in China. Owing to its minor side effects and good curative efficacy, the screening of anticancer drugs from traditional Chinese herbal medicine has increased considerably over the past few years [7,8].Myrica rubra (Lour.) Sieb. Et Zucc., a myricaceae Myrica plant, found in China and other Asian countries. Because of its biological properties, the bark of M. rubra is used in Chinese folk medicine [9][10][11]. Myricanol is a cyclic diarylheptanoid isolated from the bark of M. rubra. Diarylheptanoids exhibit various biological activities, including antitumor [12], antiviral [13], antioxidant [14] and anti-inflammatory [15] owing to its unique chemical structure. Our previous studies have shown that myricanol significantly inhibits the proliferation of human lung adenocarcinoma (A549), hepatoma (HepG2) and human promyelocytic leukemia (HL-60) cells. Further, it increased the caspase-3, caspase-9, Bax and p21 expression and decreased the expressions of Bcl-2 at the mRNA and protein levels [16]. Myricanol significantly induced tumor growth inhibitory effects on the xenografts of lung adenocarcinoma A549 by upregulating the expression of Bax and downregulating that of survivin, Bcl-2, VEGF and HIF-1α. The experimentation has indicated that the possible antitumor effects of myricanol are via the mitochondrial apoptosis pathway [17].In order to improve anticancer effect of myricanol, and to further explore the structure-activity relationship of myricanol and discover novel myricanol derivatives as antitumor agents, some novel myricanol derivatives, such as 5-fluorobenzyloxy ether (5FEM), myricanol 5-chlorobe...

show abstract

Section: Discussionmentioning

confidence: 99%

The Mechanistic Antitumor Study of Myricanol 5-Fluorobenzyloxy Ether in Human Leukemic Cell Hl-60

Dai

Fan

Ren³

et al. 2017

Future Med. Chem.

View full text Add to dashboard Cite

show abstract

“…Studies have demonstrated that p300/CBP activity can be targeted by curcumin in cervical and other cancers [46,47] . There are also lines of evidence showing that curcumin prevents histone hyperacetylation and alters miRNA expression in cancers other than cervical cancer [48,49] . Similarly, genistein is known to affect histone acetylation or DNA methylation [50,51] Alcohol consumption and smoking are important risk factors for cervical carcinogenesis.…”

Section: Nutrition Diet Epigenetics and Cervical Cancermentioning

confidence: 99%

Epigenomics, Pharmacoepigenomics, and Personalized Medicine in Cervical Cancer

Kabekkodu

Chakrabarty

Ghosh

et al. 2017

Public Health Genomics

View full text Add to dashboard Cite

Epigenomics encompasses the study of genome-wide changes in DNA methylation, histone modifications and noncoding RNAs leading to altered transcription, chromatin structure, and posttranscription RNA processing, respectively, resulting in an altered rate of gene expression. The role of epigenetic modifications facilitating human diseases is well established. Previous studies have identified histone and cytosine code during normal and pathological conditions with special emphasis on how these modifications regulate transcriptional events. Recent studies have also mapped these epigenetic modification and pathways leading to carcinogenesis. Discovery of drugs that target proteins/enzymes in the epigenetic pathways may provide better therapeutic opportunities, and identification of such modulators for DNA methylation, histone modifications, and expression of noncoding RNAs for several cancer types is underway. In this review, we provide a detailed description of recent developments in the field of epigenetics and its impact on personalized medicine to manage cervical cancer.

show abstract

“…Sometimes, the reason of the deregulation of these microRNAs is known e over 50% of microRNAs are situated on fragile genomic regions in cancer [10,11]. Sometimes, their functions were even decrypted, leading to the concept of oncomiRs and microRNA tumor suppressors [3,5,11].…”

mentioning

confidence: 99%

“…Concretely, there are only 2 microRNA-related drugs in Phase 1 and Phase 2 of clinical trials respectively: Mirna Therapeutics started in 2013 to test the microRNA mimic of miR-34a, a tumor suppressor regulating at least 24 oncogenes, in patients suffering from primary liver cancer and liver metastases [10,15]. Good results were obtained in the meantime by Miravirsen, which antagonizes miR-122, essential for hepatitis C virus (HCV) replication [7].…”

mentioning

confidence: 99%